AcademyHealth: How should we pay for gene therapy?

For many, many years we’ve been hearing about gene therapy – the chance that we can get into people’s DNA and fix it to resolve problems and fix disease. In a recent piece in Science, Stuart Orkin and Philip Reilly discuss what finally achieving success might mean:

Go read about that, and what I think about it, over at the AcademyHealth blog! Go!

@aaronecarroll

Aaron Carroll

Aaron E. Carroll, MD, MS is co-Editor-in-Chief of The Incidental Economist. He is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all. In addition to contributing regularly to The New York Times and the Atlantic, he is the author of four books, most recently The Bad Food Bible.

Hidden information below

Aaron Carroll

Aaron E. Carroll, MD, MS is co-Editor-in-Chief of The Incidental Economist. He is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all. In addition to contributing regularly to The New York Times and the Atlantic, he is the author of four books, most recently The Bad Food Bible.

The Incidental Economist

the health services research blog

WordPress Management: BKJ Productions
Editors In Chief
Content Manager

Work posted here under copyright © of the authors • Details on the Site Policies page

Subscribe

Email Address*